Clinical trials · Los Angeles, CA
Urothelial Cancer clinical trials in Los Angeles
We’re tracking 37 recruiting urothelial cancer studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 2/Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Los Angeles, CaliforniaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide study for early bladder cancer in men
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Los Angeles, CaliforniaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Los Angeles, CaliforniaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Los Angeles, CaliforniaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Los Angeles, CaliforniaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Study of datopotamab deruxtecan with chemo for advanced bladder cancer
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07421700RecruitingPhase 1/Phase 2
Study of PF-08634404 alone or with enfortumab vedotin for bladder cancer
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05775471RecruitingPhase 2
Check PD-1 plus enfortumab after kidney-urine-duct surgery
This Phase 2 study tests giving pembrolizumab (an immune therapy) and enfortumab vedotin (an antibody-drug medicine) before and after surgery to remove high-risk upper urinary tract cancer. The goal is to lower the chance the cancer comes back.
Los Angeles, CaliforniaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Los Angeles, CaliforniaAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Los Angeles, CaliforniaAges 18–75 - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Los Angeles, CaliforniaAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Urothelial Cancer trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
Urothelial Cancer trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting urothelial cancer studies listed above.
- City of Hope Comprehensive Cancer Center · 9 studies
- USC / Norris Comprehensive Cancer Center · 9 studies
- Cedars-Sinai Medical Center · 4 studies
- Los Angeles General Medical Center · 4 studies
- University of California, Los Angeles (UCLA) · 4 studies
- University of Southern California · 4 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 3 studies
- UCLA / Jonsson Comprehensive Cancer Center · 3 studies
What taking part in a urothelial cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting urothelial cancer studies in California.
Common questions
- Are there urothelial cancer clinical trials near Los Angeles?
- Yes. We're currently tracking 37 recruiting urothelial cancer studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a urothelial cancer study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a urothelial cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New urothelial cancer studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.